Due to their cardiorenal benefits, most clinical guidelines recommend SGLT2 inhibitors and GLP-1 RAs as first-line treatment for individuals with type 2 diabetes at very high cardiorenal risk [8–12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.